Researchers may have defined a safer and less expensive way to determine the presence of food allergy in children, according to new research in the Journal of Allergy & Clinical Immunology (JACI). The JACI is the peer-reviewed scientific journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).
An asthma intervention program applied during the first year of life significantly reduced the prevalence of asthma in high risk children at 7 years of age, according to a new study featured on the online version of the Journal of Allergy & Clinical Immunology (JACI). The JACI is the peer-reviewed journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).
Day care facilities were shown to be an important source for allergen exposure, according to a study featured on the online version of the Journal of Allergy & Clinical Immunology (JACI). The JACI is the peer-reviewed journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).
Children who have asthma/bronchitis at five years of age may be at an increased risk of developing certain behavioral problems as teenagers, a recent report shows.
If your child has asthma, the National Jewish Medical and Research Center in Denver suggests you make sure the school is properly alerted to your child’s condition:
The only advice doctors can give to the 4 percent of Americans with potentially life-threatening food allergies is to avoid the culprit food, often nuts or shellfish. But that may change as researchers in a new Food Allergy Research Consortium, announced, strive to develop therapies to treat and prevent food allergy.
The Food and Drug Administration (FDA) announced the tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories Limited, Guragon, India and Aurobindo Pharma Limited, Hyderabad, India. These are the first generic versions of Viramune Tablets manufactured by Boehringer Ingelheim. These products will now be available for consideration for purchase under the President?s Emergency Plan for AIDS Relief (PEPFAR).
The Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services (HHS) announced the tentative approval of efavirenz tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. This product is the first tentatively approved generic version of Sustiva Tablets (manufactured by Bristol-Myers Squibb). Efavirnez will now be available for consideration for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR).
The Food and Drug Administration (FDA) announced the approval of Aptivus (tipranavir) capsules, an HIV protease inhibitor, to be given with ritonavir for treatment of HIV-1 infected adults. This is the second drug approved for patients with advanced HIV disease, and provides a new therapy for patients with limited treatment options.
Ear surgery, or otoplasty, is usually done to set prominent ears back closer to the head or to reduce the size of large ears.